ClinicalTrials.Veeva

Menu
F

Finlay Medical Research | Miami, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Olezarsen
Bococizumab
ISIS 678354
Vicadrostat
Donanemab
BI 655130
RTA 901
TQJ230
Empagliflozin
VY7523-102

Parent organization

This site is a part of Finlay Medical Research

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

21 of 43 total trials

A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD). Approxi...

Enrolling
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.Additional part...

Active, not recruiting
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Active, not recruiting
Primary Prevention of Atherosclerotic Cardiovascular Disease
Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
Drug: Placebo in 1.5ml

The purpose of the study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from bas...

Active, not recruiting
Severe Hypertriglyceridemia
Drug: Olezarsen
Drug: Placebo

The purpose of this study is to demonstrate the efficacy of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) compared to placeb...

Active, not recruiting
Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
Biological: ExPEC9V
Other: Placebo

Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Cli...

Active, not recruiting
Alzheimer's Disease (AD)
Drug: Placebo
Drug: ABBV-916

This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determining the superiorit...

Active, not recruiting
Early Alzheimer's Disease
Drug: Lecanemab
Drug: Drug: Lecanemab

The primary purpose of this study is to evaluate the efficacy of sabirnetug infusions administered once every four weeks (Q4W) in slowing cognitive a...

Active, not recruiting
Alzheimer Disease
Drug: Placebo
Drug: sabirnetug

The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmo...

Enrolling
Chronic Obstructive Pulmonary Disease
Drug: Astegolimab

This is a parallel, double blind, Phase 3, 2-arm study that is designed to provide additional safety information, assess the durability of treatment...

Active, not recruiting
Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: Itepekimab (SAR440340)

This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these cond...

Enrolling
Hypertension
Cardiovascular Diseases
Drug: Placebo matching Vicadrostat
Drug: Vicadrostat

This study is open to adults with chronic kidney disease (CKD) that is at risk of getting worse. People who have taken a specific type of medication...

Enrolling
Chronic Kidney Disease
Drug: Placebo matching vicadrostat
Drug: Vicadrostat

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD)...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Obicetrapib
Drug: Placebo

The purpose of this study is to evaluate the safety and tolerability of olezarsen in participants with SHTG.

Enrolling
Severe Hypertriglyceridemia
Drug: Olezarsen

The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of car...

Enrolling
Overweight
Atherosclerotic Cardiovascular Disease
Drug: Maridebart Cafraglutide
Drug: Placebo

Study CTQJ230A12303 is a randomized, double-blind placebo-controlled, Phase IIIb study to evaluate the efficacy, safety and tolerability of pelacarse...

Active, not recruiting
Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease
Drug: TQJ230
Drug: Placebo

This non-randomized, rollover extension study will provide post-trial access to pelacarsen (TQJ230) to participants who have successfully completed e...

Enrolling
Atherosclerotic Cardiovascular Disease
Drug: Pelacarsen (TQJ230)

This Phase 1b study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of multiple IV infusions...

Enrolling
Alzheimer Disease, Early Onset
Drug: Placebo
Drug: PMN310

Primary Objective:Primary population (former smokers cohort):* Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of ac...

Active, not recruiting
Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: Itepekimab SAR440340

The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants...

Active, not recruiting
Alzheimer Disease, Early Onset
Other: Placebo
Drug: BMS-986446

Trial sponsors

Pfizer logo
Boehringer Ingelheim logo
Ionis Pharmaceuticals logo
Novartis logo
Sanofi logo
D
Lilly logo
Roche logo
AbbVie logo
Abbott logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems